Literature DB >> 28762491

Generation of Recombinant Vaccinia Viruses.

Linda S Wyatt1, Patricia L Earl1, Bernard Moss1.   

Abstract

This unit describes how to infect cells with vaccinia virus and then transfect them with a plasmid-transfer vector or PCR fragment to generate a recombinant virus. Selection and screening methods used to isolate recombinant viruses and a method for the amplification of recombinant viruses are described. Finally, a method for live immunostaining that has been used primarily for detection of recombinant modified vaccinia virus Ankara (MVA) is presented. © 2017 by John Wiley & Sons, Inc.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Mesh：

Year:  2017        PMID： 28762491      PMCID： PMC5765993          DOI： 10.1002/cpps.33

Source DB:  PubMed          Journal:  Curr Protoc Protein Sci        ISSN： 1934-3655


  28 in total

1.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain.

Authors:  F Scheiflinger; F G Falkner; F Dorner
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses.

Authors:  M W Carroll; B Moss
Journal:  Biotechniques       Date:  1995-09       Impact factor: 1.993

4.  A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells.

Authors:  D D Patel; C A Ray; R P Drucker; D J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

7.  A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.

Authors:  G Sutter; L S Wyatt; P L Foley; J R Bennink; B Moss
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

8.  Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.

Authors:  Linda S Wyatt; Patricia L Earl; Wei Xiao; Jeffrey L Americo; Catherine A Cotter; Jennifer Vogt; Bernard Moss
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

9.  One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription.

Authors:  C Bertholet; R Drillien; R Wittek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

10.  Preparation of Cell Cultures and Vaccinia Virus Stocks.

Authors:  Catherine A Cotter; Patricia L Earl; Linda S Wyatt; Bernard Moss
Journal:  Curr Protoc Protein Sci       Date:  2017-08-01
View more
  4 in total

1.  MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.

Authors:  Ethan Laudermilch; Kartik Chandran
Journal:  J Mol Biol       Date:  2021-02-24       Impact factor: 5.469

2.  Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.

Authors:  Flavia Chiuppesi; Marcela d'Alincourt Salazar; Heidi Contreras; Vu Nguyen; Joy Martinez; Soojin Park; Jenny Nguyen; Mindy Kha; Angelina Iniguez; Qiao Zhou; Teodora Kaltcheva; Roman Levytskyy; Nancy Ebelt; Tae Kang; Xiwei Wu; Tom Rogers; Edwin Manuel; Yuriy Shostak; Don Diamond; Felix Wussow
Journal:  Res Sq       Date:  2020-07-17

3.  Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies.

Authors:  Chaojie Zhong; Hongjie Xia; Awadalkareem Adam; Binbin Wang; Renee L Hajnik; Yuejin Liang; Grace H Rafael; Jing Zou; Xiaofang Wang; Jiaren Sun; Lynn Soong; Alan D T Barrett; Scott C Weaver; Pei-Yong Shi; Tian Wang; Haitao Hu
Journal:  NPJ Vaccines       Date:  2021-11-29       Impact factor: 9.399

4.  Efficient Method for Generating Point Mutations in the Vaccinia Virus Genome Using CRISPR/Cas9.

Authors:  Laetitia Boutin; Estelle Mosca; Frédéric Iseni
Journal:  Viruses       Date:  2022-07-18       Impact factor: 5.818
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.